Compare QUBT & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUBT | NBTX |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2019 | 2018 |
| Metric | QUBT | NBTX |
|---|---|---|
| Price | $7.96 | $35.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $17.50 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 12.6M | 80.4K |
| Earning Date | 05-13-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $682,000.00 | N/A |
| Revenue This Year | $3,210.56 | $58.17 |
| Revenue Next Year | $51.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 82.84 | N/A |
| 52 Week Low | $6.18 | $4.93 |
| 52 Week High | $25.84 | $57.14 |
| Indicator | QUBT | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 43.42 |
| Support Level | $7.79 | $30.15 |
| Resistance Level | $13.19 | $38.29 |
| Average True Range (ATR) | 0.56 | 2.57 |
| MACD | -0.11 | -0.17 |
| Stochastic Oscillator | 20.88 | 9.47 |
Quantum Computing Inc is an integrated photonics and non-linear quantum optics company to develop and deliver machines for quantum computing, reservoir computing, and remote sensing, imaging, and cybersecurity applications based on patented and proprietary photonics technology. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offers capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.